Cargando…

Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is the most malignant and common form of neuroendocrine lung cancer with pure (P‐SCLC) and combined subtypes (C‐SCLC). However, little is known about the differences between these two groups and in this study we aimed to provide a more comprehensive insight...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yujing, Wang, Yanan, Zhou, Wensheng, Chen, Ya, Lou, Yuqing, Qian, Fangfei, Lu, Jun, Jiang, Haohua, Xiang, Biao, Zhang, Yanwei, Han, Baohui, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527167/
https://www.ncbi.nlm.nih.gov/pubmed/36054506
http://dx.doi.org/10.1111/1759-7714.14604
_version_ 1784801025048182784
author Li, Yujing
Wang, Yanan
Zhou, Wensheng
Chen, Ya
Lou, Yuqing
Qian, Fangfei
Lu, Jun
Jiang, Haohua
Xiang, Biao
Zhang, Yanwei
Han, Baohui
Zhang, Wei
author_facet Li, Yujing
Wang, Yanan
Zhou, Wensheng
Chen, Ya
Lou, Yuqing
Qian, Fangfei
Lu, Jun
Jiang, Haohua
Xiang, Biao
Zhang, Yanwei
Han, Baohui
Zhang, Wei
author_sort Li, Yujing
collection PubMed
description BACKGROUND: Small cell lung cancer (SCLC) is the most malignant and common form of neuroendocrine lung cancer with pure (P‐SCLC) and combined subtypes (C‐SCLC). However, little is known about the differences between these two groups and in this study we aimed to provide a more comprehensive insight into SCLC. METHODS: Data from 580 postoperative patients with pathologically confirmed SCLC in Shanghai Chest Hospital from January 2010 to December 2020 were collected retrospectively. The clinical characteristics and prognosis were analyzed. RESULTS: A total of 357 P‐SCLC patients and 223 C‐SCLC patients were included. The results indicated that P‐SCLC appeared to have a higher proportion of being located in the middle lobe than C‐SCLC. The incidences of P‐SCLC in patients with visceral pleural invasion (VPI) and in stage II were higher than C‐SCLC, while C‐SCLC was more likely to be accompanied by higher incidences of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) rearrangement, and higher levels of CEA, SCCA and CYFRA21‐1 than P‐SCLC. The most common were SCLC combined with large cell neuroendocrine components among 223 C‐SCLCs. Survival analysis confirmed a more favorable disease‐free survival (DFS) (p = 0.016) and overall survival (OS) (p = 0.024) in patients with P‐SCLCs compared with C‐SCLCs. Histological type, tumor location, pN stage, adjuvant chemotherapy, serum NSE and CA125 levels were independent risk factors for survival rate in SCLC. In addition, adjuvant chemotherapy was beneficial in improving stage I P‐SCLC and C‐SCLC DFS and OS rates, and similar results were not seen in adjuvant radiation therapy. CONCLUSIONS: Patients with C‐SCLC have a poorer prognosis than P‐SCLC patients. We determined that large cell neuroendocrine carcinoma was the most common additional component of C‐SCLC, and patients with this component appeared to have a longer DFS and OS than other combined components.
format Online
Article
Text
id pubmed-9527167
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-95271672022-10-06 Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer Li, Yujing Wang, Yanan Zhou, Wensheng Chen, Ya Lou, Yuqing Qian, Fangfei Lu, Jun Jiang, Haohua Xiang, Biao Zhang, Yanwei Han, Baohui Zhang, Wei Thorac Cancer Original Articles BACKGROUND: Small cell lung cancer (SCLC) is the most malignant and common form of neuroendocrine lung cancer with pure (P‐SCLC) and combined subtypes (C‐SCLC). However, little is known about the differences between these two groups and in this study we aimed to provide a more comprehensive insight into SCLC. METHODS: Data from 580 postoperative patients with pathologically confirmed SCLC in Shanghai Chest Hospital from January 2010 to December 2020 were collected retrospectively. The clinical characteristics and prognosis were analyzed. RESULTS: A total of 357 P‐SCLC patients and 223 C‐SCLC patients were included. The results indicated that P‐SCLC appeared to have a higher proportion of being located in the middle lobe than C‐SCLC. The incidences of P‐SCLC in patients with visceral pleural invasion (VPI) and in stage II were higher than C‐SCLC, while C‐SCLC was more likely to be accompanied by higher incidences of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) rearrangement, and higher levels of CEA, SCCA and CYFRA21‐1 than P‐SCLC. The most common were SCLC combined with large cell neuroendocrine components among 223 C‐SCLCs. Survival analysis confirmed a more favorable disease‐free survival (DFS) (p = 0.016) and overall survival (OS) (p = 0.024) in patients with P‐SCLCs compared with C‐SCLCs. Histological type, tumor location, pN stage, adjuvant chemotherapy, serum NSE and CA125 levels were independent risk factors for survival rate in SCLC. In addition, adjuvant chemotherapy was beneficial in improving stage I P‐SCLC and C‐SCLC DFS and OS rates, and similar results were not seen in adjuvant radiation therapy. CONCLUSIONS: Patients with C‐SCLC have a poorer prognosis than P‐SCLC patients. We determined that large cell neuroendocrine carcinoma was the most common additional component of C‐SCLC, and patients with this component appeared to have a longer DFS and OS than other combined components. John Wiley & Sons Australia, Ltd 2022-08-29 2022-10 /pmc/articles/PMC9527167/ /pubmed/36054506 http://dx.doi.org/10.1111/1759-7714.14604 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Li, Yujing
Wang, Yanan
Zhou, Wensheng
Chen, Ya
Lou, Yuqing
Qian, Fangfei
Lu, Jun
Jiang, Haohua
Xiang, Biao
Zhang, Yanwei
Han, Baohui
Zhang, Wei
Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
title Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
title_full Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
title_fullStr Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
title_full_unstemmed Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
title_short Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
title_sort different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527167/
https://www.ncbi.nlm.nih.gov/pubmed/36054506
http://dx.doi.org/10.1111/1759-7714.14604
work_keys_str_mv AT liyujing differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT wangyanan differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT zhouwensheng differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT chenya differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT louyuqing differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT qianfangfei differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT lujun differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT jianghaohua differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT xiangbiao differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT zhangyanwei differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT hanbaohui differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer
AT zhangwei differentclinicalcharacteristicsandsurvivalbetweensurgicallyresectedpureandcombinedsmallcelllungcancer